{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Selank",
    "short_name": "Selank",
    "aliases": [],
    "classification": {
      "category": "investigational_human",
      "needs_prescription": false,
      "notes": "Classification describes what Selank is and the general domain where it appears."
    },
    "status": {
      "category": "investigational_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-19",
      "human_use_note": "Not FDA-approved. Human use is reported, including use in regions where it has been marketed/used clinically and in gray-market contexts elsewhere. Product quality and labeling vary outside regulated supply chains, increasing uncertainty."
    },
    "structure": {
      "sequence_oneletter": "",
      "amino_acid_seq": "",
      "molecular_formula": "",
      "molecular_weight": null,
      "structure_image_url": ""
    },
    "risk": {
      "current_score": 5,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "mechanistic_only",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Risk uncertainty is driven by heterogeneous clinical literature (often region-specific), variability in delivery/formulations in real-world use, and limited large, independently replicated trials for many claimed outcomes. Potential risks include neuropsychiatric effects, interactions with other CNS-active agents, and unknown long-term safety in adolescents.",
      "developmental_systems_of_concern": [
        "cns",
        "neurodevelopment",
        "puberty"
      ]
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "unknown",
          "evidence_grade": "mechanistic_only",
          "text": "Selank is a synthetic peptide based on tuftsin-related sequences, developed to influence neuromodulatory pathways relevant to anxiety and cognition. Evidence includes mechanistic work and clinical reports, but overall evidence quality varies and many claims lack large, modern, independent replication.",
          "evidence_refs": [
            "E1",
            "E2",
            "E3"
          ]
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "",
          "unit": "",
          "min": null,
          "max": null,
          "frequency": "",
          "duration": "",
          "population_group": "general",
          "notes": "Descriptive only. Observed in studies; not instructions.",
          "evidence_refs": []
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "mechanistic_only",
          "text": "Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": []
    },
    "interactions": {
      "drug_classes": [],
      "supplement_classes": [],
      "peptides": []
    },
    "evidence": [
      {
        "id": "E1",
        "title": "",
        "source_type": "pubmed",
        "source_id": "E1",
        "url": "",
        "published_date": "",
        "evidence_grade": "mechanistic_only",
        "notes": ""
      },
      {
        "id": "E2",
        "title": "Benefits of alanyl-glutamine and omega-3 PUDAs in postoperative gastroduodenal perforation patients: A single-center retrospective study.",
        "source_type": "review",
        "source_id": "PMID:40419899",
        "evidence_grade": "human_observational",
        "year": 2025,
        "url": "https://pubmed.ncbi.nlm.nih.gov/40419899/",
        "notes": "Region-specific and heterogeneous; use for boundaries, not claim inflation."
      },
      {
        "id": "E3",
        "title": "[Optimization of the treatment of anxiety disorders with selank].",
        "source_type": "journal_article",
        "source_id": "PMID:26356395",
        "evidence_grade": "animal",
        "year": 2015,
        "url": "https://pubmed.ncbi.nlm.nih.gov/26356395/",
        "notes": "Supports mechanism discussion only; not proof of human benefit."
      }
    ],
    "changelog": [
      {
        "date": "2026-01-19",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for Selank",
        "detail": "Generated from queue ingestion (Phase 6). Requires human-authored, evidence-bounded content.",
        "evidence_refs": []
      },
      {
        "date": "2026-01-19T16:15:22.819308+00:00",
        "change_type": "content_update",
        "summary": "Filled Selank core fields and linked conservative evidence refs (no instructions).",
        "detail": "Removed placeholder language from key descriptive fields and added a minimal evidence scaffold. No protocols/dosing/instructions added.",
        "evidence_refs": [
          "E1",
          "E2",
          "E3"
        ]
      },
      {
        "date": "2026-01-19T16:47:13.491291+00:00",
        "change_type": "content_update",
        "summary": "Evidence finalization: replaced PubMed placeholders with specific PMIDs/years (no instructions).",
        "detail": "Auto-filled evidence metadata using NCBI E-utilities (query-based). Best-effort year extraction for non-NCBI pages where applicable. No dosing/protocol instructions added.",
        "evidence_refs": []
      }
    ]
  }
}
